About Rho GTPase-activating protein 15
Rho GTPase-activating protein 15 (ARHGAP15) is a protein
from Homo sapiens identified by UniProt accession
Q53QZ3, 475 residues long.
MolForge cross-references it against 0 known binders and
249 disease associations.
Target properties
| Protein name | Rho GTPase-activating protein 15 |
| UniProt accession | Q53QZ3 |
| Gene | ARHGAP15 |
| Organism | Homo sapiens |
| Length | 475 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (249)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.50
- mean platelet volume · score 0.49
- eosinophil count · score 0.48
- leukocyte count · score 0.48
- body mass index · score 0.47
- platelet count · score 0.46
- lymphocyte percentage of leukocytes · score 0.46
- platelet component distribution width · score 0.46
- neutrophil percentage of leukocytes · score 0.46
- myeloid white cell count · score 0.45
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q53QZ3-F1 | alphafold | PREDICTED | 76.05 | — |
Amino-acid sequence (475 residues)
MQKSTNSDTS VETLNSTRQG TGAVQMRIKN ANSHHDRLSQ SKSMILTDVG KVTEPISRHR RNHSQHILKD VIPPLEQLMV EKEGYLQKAK IADGGKKLRK NWSTSWIVLS SRRIEFYKES KQQALSNMKT GHKPESVDLC GAHIEWAKEK SSRKNVFQIT TVSGNEFLLQ SDIDFIILDW FHAIKNAIDR LPKDSSCPSR NLELFKIQRS SSTELLSHYD SDIKEQKPEH RKSLMFRLHH SASDTSDKNR VKSRLKKFIT RRPSLKTLQE KGLIKDQIFG SHLHKVCERE NSTVPWFVKQ CIEAVEKRGL DVDGIYRVSG NLATIQKLRF IVNQEEKLNL DDSQWEDIHV VTGALKMFFR ELPEPLFPYS FFEQFVEAIK KQDNNTRIEA VKSLVQKLPP PNRDTMKVLF GHLTKIVAKA SKNLMSTQSL GIVFGPTLLR AENETGNMAI HMVYQNQIAE LMLSEYSKIF GSEED
Explore Rho GTPase-activating protein 15 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets